alexa Bioequivalence Study of Norfloxacin Tablets (OranorÂ
ISSN: 0975-0851

Journal of Bioequivalence & Bioavailability
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article

Bioequivalence Study of Norfloxacin Tablets (Oranor® and Noroxin®) in Healthy Male Volunteers. A Single Dose, Randomized, Open-label, 2 x 2 Cross-over, in Fasting Conditions Study

Rosalba Alonso-Campero1,2*, Roberto Bernardo-Escudero1, María Teresa de Jesús Francisco-Doce3, Myriam Cortés-Fuentes3, Gilberto Castañeda-Hernandez2 and Mario I. Ortiz4

1Asociación Mexicana para la Investigación Clínica, A.C. Pachuca Hidalgo, México

2Departamento de Farmacología, Centro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional, México, D.F., México

3Centro A.F. de Estudios Tecnológicos, S.A. México DF

4Laboratorio de Farmacología del Área Académica de Medicina del Instituto de Ciencias de la Salud, Universidad Autónoma del Estado de Hidalgo. Pachuca, Hidalgo, México

*Corresponding Author:
Dr. Rosalba Alonso-Campero
Cumbres 107, Ciudad de los Niños. Pachuca
Hidalgo, México. 42090
Tel: +52 7717144377
Fax: +52 7717144299
E-mail: [email protected]

Received Date: October 12, 2011; Accepted Date: October 29, 2011; Published Date: October 31, 2011

Citation: Alonso-Campero R, Bernardo-Escudero R, de Jesús Francisco-Doce MT, Cortés-Fuentes M, Castañeda-Hernandez G, et al. (2011) Bioequivalence Study of Norfloxacin Tablets (Oranor® and Noroxin®) in Healthy Male Volunteers. A Single Dose, Randomized, Open-label, 2 x 2 Cross-over, in Fasting Conditions Study. J Bioequiv Availab 3: 215-221. doi: 10.4172/jbb.1000089

Copyright: © 2011 Alonso-Campero R, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

 

Abstract

Background: Norfloxacin is a fluoroquinolone antibacterial agent suitable for oral administration. This study evaluates if the fasting bioavailability of two solid formulations of 400 mg of norfloxacin is equivalent for obtaining marketing approval from the Mexican regulatory agency. Objective: Establish and compare the comparable bioavailability of 400 mg norfloxacin coated tablets (Oranor  ) and 400 mg norfloxacin tablets (Noroxin  ) after administration of an oral dose, in fasting conditions, in healthy male subjects. Subjects and methods: This was a 2 x 2 cross-over, randomized, single-dose, open-label study which included 26 healthy male subjects under fasting conditions. In each of the two study periods (separated by a washout of 7 days) a single dose of test or reference drug was administered. Blood samples were taken up to 24 h post dose, the plasma was separated and the concentrations of norfloxacin were determined by a high performance liquid chromatography with fluorescence detection. Schüirmann’s unilateral double t- test and confidence interval of 90% to norfloxacin concludes that the bioavailability of C max and AUC results between the two treatments are equivalent. Results: All 26 subjects were included in the analysis mean ± SD age: 31±7.51 years, height: 168±6.95 cm, weight: 69.58±8.53 kg and body mass index: 24.37±2.02 kg/m 2 . All were Hispanic (Mexicans). The mean AUC 0-t , AUC 0- ∞, C max , t max and t½ were 6228.18 ng/h/mL, 6658.62 ng/h/mL, 1436.19 ng/mL, 1.38 h and 6.51 h, respectively, for the test drug and 6706.32 ng/h/mL, 7161.03 ng/h/ml, 1470.14 ng/mL, 1.40 h and 6.55 h respectively, for the reference product. Conclusions: This single dose study in a small population of fasting, healthy subjects found no statistically significant differences in bioavailability (C max and AUC) between the test and reference products, meeting the National Ministry of Health regulatory requirements in México for assuming equivalence. Both formulations were well tolerated

Keywords

Share This Page

Additional Info

Loading
Loading Please wait..
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords